Gemcitabine and pemetrexed disodium in treating breast cancer

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase. This agent is broadly active in a wide variety of solid tumors, including breast cancer. Pemetrexed disodium has also shown clinically relevant activity in combination with gemcitabine (Gemzar). This combination is being evaluated for the treatment of metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)34-37
Number of pages4
JournalOncology
Volume15
Issue number2 SUPPL. 3
StatePublished - Dec 1 2001

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Gemcitabine and pemetrexed disodium in treating breast cancer'. Together they form a unique fingerprint.

  • Cite this